ctDNA Tracks Relapse Risk in Breast Cancer - Takeaways - MDSpire

ctDNA Tracks Relapse Risk in Breast Cancer

Share

1

ctDNA monitoring predicted relapse and survival outcomes in early breast cancer more accurately than standard treatment response measures.
2

The study followed 136 patients and analyzed nearly 1,500 plasma samples over a median follow-up of 6.5 years.
3

Persistence of ctDNA after neoadjuvant therapy was strongly associated with higher recurrence and death rates.
4

ctDNA detection often preceded clinical relapse by a median of 13.8 months, indicating its potential for early intervention.
5

The assay targets tumor-specific structural variants, offering greater specificity and stability for longitudinal monitoring.